The Weight-Loss Drug That Wins on Hearts, Not on Pounds

Key Takeaway

A head-to-head comparison based on the first large-scale real-world data demonstrates that semaglutide, not tirzepatide, provides a greater reduction in the risk of heart attack, stroke, and death in patients with obesity and established atherosclerotic disease. Greater weight loss did not translate to greater cardiovascular protection—a long-overdue correction to an assumption that had quietly become doctrine in prescribing practice.

The Unquestioned Prescription

The patient is a 62-year-old man who had an anterior myocardial infarction fourteen months ago and is on a high-intensity statin, an ACE inhibitor, and aspirin. His body mass index is 33, and his hemoglobin A1c is 5.6%. He has researched both injectable medications and wants the one that works better—the one that will deliver the fastest results on the scale. For two years, the answer to this question was simple: Tirzepatide, with its approximately 21% weight loss at the highest dose in phase 3 trials, had outperformed all preceding incretin agents.^[2] Clinicians extrapolated from this data: the drug that melts the most visceral fat would undoubtedly provide the best protection for coronary arteries. However, a new analysis of over 21,000 matched patients shows this inference was incorrect.

The Study

The STEER analysis was a retrospective observational cohort study conducted using a large U.S. health claims database, covering patients who initiated treatment between May 2022 and January 2025. The inclusion criteria were deliberately narrow and clinically recognizable: patients aged 45 and older, overweight or obese, without diabetes, and with a diagnosis of established atherosclerotic disease (defined by at least one health claim for myocardial infarction, ischemic stroke, or peripheral artery disease). In other words, this population was similar to the patient group in the SELECT trial, but these were real-world patients encountered in routine clinical practice. The researchers used propensity score matching to balance baseline characteristics between the groups using each drug, creating cohorts of 10,625 patients each^[1]. The endpoints were a modified three-point MACE (myocardial infarction, stroke, all-cause mortality) and a modified five-point MACE, which added coronary revascularization and hospitalization for heart failure. Cox proportional hazards models were used to compare the time to the first event; a secondary per-protocol analysis censored patients with any treatment gap exceeding 30 days.

A closer look at the clinical background of the matched patient cohort reveals a population with a decidedly high-risk atherosclerotic profile. Approximately 73% of patients had hypertension, 71% had dyslipidemia, and more than a third had obstructive sleep apnea. Crucially, the rates of guideline-directed medical therapy (GDMT) were nearly identical in both arms: about 6 out of 10 patients were on regular statin therapy, while 40% were on a beta-blocker, 30% on an angiotensin receptor blocker (ARB), and 20% on an ACE inhibitor. The mean follow-up period was 8.3 months for the semaglutide group and 8.6 months for the tirzepatide group.

Key Findings

Compared to tirzepatide, semaglutide was associated with a 29% lower risk of the three-component MACE (hazard ratio 0.71; p = 0.046) and a 22% lower risk of the five-component MACE (HR 0.78; p = 0.040)^[1]. When the analysis was restricted to periods of continuous treatment, this separation became markedly more pronounced, with an HR of 0.43 for three-component MACE (p = 0.005) and an HR of 0.57 for five-component MACE (p = 0.003)^[1]. The event curves diverged far earlier than the time frame in which the weight-loss trajectories of these two agents would be expected to differ significantly. For comparison, the SELECT trial demonstrated that semaglutide provided a 20% relative risk reduction in MACE compared to placebo in patients with the same phenotype^[3], whereas tirzepatide’s diabetes-specific outcome trial showed non-inferiority, not superiority, against dulaglutide^[4].

The widening gap observed in the per-protocol analysis revealed an even more striking picture in organ-specific individual outcomes. Among patients who remained on continuous therapy, semaglutide use was associated with a 62% reduction in the risk of myocardial infarction (HR 0.38; p = 0.019) and a 66% reduction in the risk of hospitalization for heart failure (HR 0.34; p = 0.020) compared to tirzepatide. Rates of stroke and coronary revascularization also showed a strong trend in favor of semaglutide, though they did not reach statistical significance. Another noteworthy finding was the dose dynamics: by the end of the follow-up period, only 21.7% of semaglutide patients had reached the target maintenance dose of 2.4 mg, and only 7.2% of tirzepatide patients had reached the highest dose of 15 mg. Despite this, the cardiovascular protection curves began to separate significantly in favor of semaglutide within the first 2-3 months, indicating that the vascular benefit was associated with an early cellular protective shield triggered by the molecule, rather than its maximum dose or the cumulative weight-loss plateau.

The Underlying Mechanism

While weight loss is the most obvious effect of these drugs, it is likely the least consequential for atherosclerotic plaque. GLP-1 receptors are expressed in the endothelium, vascular smooth muscle cells, cardiomyocytes, macrophages, and the sinoatrial node. Receptor agonism suppresses NF-κB-mediated inflammatory signaling pathways within plaque, reduces monocyte adhesion and macrophage foam cell activity, improves nitric oxide-dependent vasodilation, and lowers high-sensitivity C-reactive protein independently of adiposity. When modest reductions in systolic blood pressure, triglyceride-rich lipoprotein flux, and epicardial adipose tissue volume are added to this picture, the result is a plaque-stabilizing package of effects that does not require a significant change on the scale. The SELECT trial fully supports this interpretation: despite a mean placebo-adjusted weight loss of only about 8.5 percentage points, MACE was reduced by 20%^[5], with parallel benefits observed in kidney endpoints^[6]. Tirzepatide’s additional GIP receptor agonism is an excellent metabolic accelerator for adipose tissue distribution and glycemia; however, GIP receptor biology in the vessel wall is far less defined, and there is no reason to assume this effect inherits the anti-atherosclerotic behavior of GLP-1^[7]. Tirzepatide clearly appears to benefit the congestive, obese heart failure phenotype^[8]; this physiology is distinct from that of a lipid-rich coronary lesion.

Study Limitations

This is not a randomized trial but a health claims data analysis. Data on body mass index, attained drug dose, blood pressure, lipid levels, and imaging were not available; therefore, despite propensity score matching, the presence of residual confounding is inevitable. Furthermore, channeling bias is plausible, as physicians may have directed patients at higher cardiac risk to the drug with an approved cardiovascular indication. In the intention-to-treat analyses, both p-values are close to the 0.05 threshold. The estimates in the per-protocol analysis, while presenting the most striking results, are also the most fragile, as removing patients who discontinue treatment leads to a more compliant and healthier group remaining in the analysis. The follow-up period is short, and mortality records in administrative data are incomplete.

However, beyond the inherent limitations of administrative database analyses, the study’s sponsorship and conflict-of-interest structure should not be overlooked. The fact that the STEER study was directly funded by the manufacturer of semaglutide, with in-house researchers involved in processes from protocol design to statistical analysis, heightens the need for its findings to be validated on independent clinical platforms. Additionally, the inclusion of prescriptions for off-label use of Mounjaro for weight loss in the tirzepatide cohort raises the possibility of mild insulin resistance or metabolic heterogeneity in this group that was not reflected in diagnostic codes. A definitive verdict will be rendered when the results of the ongoing randomized SURMOUNT-MMO trial, which is directly testing tirzepatide’s effect on cardiovascular morbidity and mortality against placebo, are released.

Clinical Assessment

In a patient with overweight or obesity, established atherosclerotic disease, and no diabetes, semaglutide stands out as the agent with cardiovascular benefit proven in randomized trials^[3]. This real-world data comparison further supports that semaglutide should remain the standard of care, rather than being replaced by the newer agent that is more potent for weight loss^[1]. In cases where the dominant issue is glycemia, hepatic steatosis, sleep apnea, or symptomatic heart failure due to obesity, tirzepatide remains a strong option. But when the indication is secondary prevention after an infarction or stroke, the goal is not the steepest weight-loss curve, but the flattest event curve. Until a dedicated trial evaluating tirzepatide’s outcomes in this specific population is published, this distinction should be part of patient-level discussions.

Scientific Sources

1. Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes Obes Metab. 2026;28(3):2403-2415. doi:10.1111/dom.70436. PubMed
2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PubMed
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PubMed
4. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928. PubMed
5. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049-2057. doi:10.1038/s41591-024-02996-7. PubMed
6. Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. doi:10.1038/s41591-024-03015-5. PubMed
7. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892-908. doi:10.1016/S0140-6736(25)02105-1. PubMed
8. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027. PubMed